BioSpace News Archive

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”) will host a conference call to discuss financial results for its fiscal first quarter 2023 ended December 31, 2022 and provide a corporate update on February 14, 2023 at 4:30 PM Eastern Time.

Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.

Intelligent Bio Solutions Inc., a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, announced a 1-for-20 reverse split of its common stock, effective at 5:00 P.M. Eastern Time.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI) today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Los Angeles, California.

Spinal Elements, a Carlsbad, CA-based spine technology company, announces the appointment of Ronald Lloyd as new President and Chief Executive Officer.

February 9, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”) today announces sales orders results for the year 2022 following a strong quarter for VINIA® in both the United States and Israel.

AVITA Medical, Inc. announced that it will report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Thursday, February 23, 2023.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16, at 2:20 p.m. ET.

Hepion Pharmaceuticals, Inc. announced that its CEO, Robert Foster, PharmD, PhD, will lead it in ringing the Nasdaq Closing Bell on Friday, February 10, 2023.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.